Bartlett & CO. Wealth Management LLC Sells 1,881 Shares of Becton, Dickinson and Company $BDX

Bartlett & CO. Wealth Management LLC lessened its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.3% in the 2nd quarter, HoldingsChannel reports. The fund owned 33,779 shares of the medical instruments supplier’s stock after selling 1,881 shares during the period. Bartlett & CO. Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $5,818,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Northcape Wealth Management LLC increased its stake in Becton, Dickinson and Company by 0.5% during the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock worth $2,248,000 after buying an additional 51 shares in the last quarter. Alpha Omega Wealth Management LLC boosted its stake in shares of Becton, Dickinson and Company by 5.7% in the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier’s stock worth $225,000 after acquiring an additional 53 shares during the last quarter. Brady Family Wealth LLC lifted its holdings in Becton, Dickinson and Company by 1.2% in the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier’s stock valued at $989,000 after purchasing an additional 53 shares in the last quarter. Diversified Trust Co lifted its holdings in Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock valued at $272,000 after purchasing an additional 53 shares in the last quarter. Finally, Horizon Bancorp Inc. IN lifted its holdings in Becton, Dickinson and Company by 10.9% in the 1st quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier’s stock valued at $130,000 after purchasing an additional 56 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on BDX shares. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Barclays reduced their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 3rd. Morgan Stanley lifted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Wells Fargo & Company raised their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Finally, Argus raised their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Three analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus target price of $205.40.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,023 shares of company stock valued at $562,036 over the last 90 days. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Trading Up 1.7%

Shares of BDX stock opened at $187.06 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The firm has a market cap of $53.62 billion, a PE ratio of 33.64, a price-to-earnings-growth ratio of 1.48 and a beta of 0.27. The company has a 50-day moving average of $188.55 and a two-hundred day moving average of $188.18. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. The firm had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the prior year, the business posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were paid a $1.04 dividend. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.